Literature DB >> 22869874

Tumor necrosis factor α as a master regulator of inflammation in Erdheim-Chester disease: rationale for the treatment of patients with infliximab.

Lorenzo Dagna1, Angelo Corti, Silvia Langheim, Barbara Guglielmi, Francesco De Cobelli, Claudio Doglioni, Gabriele Fragasso, Maria Grazia Sabbadini, Marina Ferrarini.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22869874     DOI： 10.1200/JCO.2012.41.9911

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  26 in total

Review 1.  Erdheim-Chester Disease: a comprehensive review of the literature.

Authors:  Roei D Mazor; Mirra Manevich-Mazor; Yehuda Shoenfeld
Journal:  Orphanet J Rare Dis       Date:  2013-09-08       Impact factor: 4.123

2.  Autoimmunity associated with Erdheim-Chester disease improves with BRAF/MEK inhibitors.

Authors:  Anaïs Roeser; Fleur Cohen-Aubart; Paul Breillat; Makoto Miyara; Jean-François Emile; Frédéric Charlotte; Jean Donadieu; Zahir Amoura; Julien Haroche
Journal:  Haematologica       Date:  2019-03-28       Impact factor: 9.941

Review 3.  Erdheim-Chester disease: a rapidly evolving disease model.

Authors:  Francesco Pegoraro; Matthias Papo; Valerio Maniscalco; Frédéric Charlotte; Julien Haroche; Augusto Vaglio
Journal:  Leukemia       Date:  2020-06-26       Impact factor: 11.528

4.  A tale of two histiocytic disorders.

Authors:  Filip Janku; Javier Munoz; Vivek Subbiah; Razelle Kurzrock
Journal:  Oncologist       Date:  2013-01-08

5.  Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease.

Authors:  Eli L Diamond; Lorenzo Dagna; David M Hyman; Giulio Cavalli; Filip Janku; Juvianee Estrada-Veras; Marina Ferrarini; Omar Abdel-Wahab; Mark L Heaney; Paul J Scheel; Nancy K Feeley; Elisabetta Ferrero; Kenneth L McClain; Augusto Vaglio; Thomas Colby; Laurent Arnaud; Julien Haroche
Journal:  Blood       Date:  2014-05-21       Impact factor: 22.113

6.  Anakinra as efficacious therapy for 2 cases of intracranial Erdheim-Chester disease.

Authors:  Eli L Diamond; Omar Abdel-Wahab; Benjamin H Durham; Ahmet Dogan; Neval Ozkaya; Lynn Brody; Maria Arcila; Christian Bowers; Mark Fluchel
Journal:  Blood       Date:  2016-08-17       Impact factor: 22.113

7.  Tocilizumab in patients with multisystem Erdheim-Chester disease.

Authors:  Alvise Berti; Giulio Cavalli; Barbara Guglielmi; Riccardo Biavasco; Corrado Campochiaro; Alessandro Tomelleri; Roberto Nicoletti; Andrea Panzacchi; Marina Ferrarini; Lorenzo Dagna
Journal:  Oncoimmunology       Date:  2017-04-20       Impact factor: 8.110

8.  A scale for patient-reported symptom assessment for patients with Erdheim-Chester disease.

Authors:  Eli L Diamond; Anne S Reiner; Justin J Buthorn; Elyse Shuk; Allison J Applebaum; David M Hyman; Omar Abdel-Wahab; Raajit Rampal; Filip Janku; Kathleen Brewer; Jean Campbell; Jun J Mao; Thomas M Atkinson; Katherine S Panageas
Journal:  Blood Adv       Date:  2019-04-09

9.  Plasma Chromogranin A as a marker of cardiovascular involvement in Erdheim-Chester disease.

Authors:  Elisabetta Ferrero; Angelo Corti; Julien Haroche; Daniela Belloni; Barbara Colombo; Alvise Berti; Giulio Cavalli; Corrado Campochiaro; Antonello Villa; Fleur Cohen-Aubart; Zahir Amoura; Claudio Doglioni; Lorenzo Dagna; Marina Ferrarini
Journal:  Oncoimmunology       Date:  2016-05-05       Impact factor: 8.110

Review 10.  Erdheim-Chester disease.

Authors:  Julien Haroche; Laurent Arnaud; Fleur Cohen-Aubart; Baptiste Hervier; Frédéric Charlotte; Jean-François Emile; Zahir Amoura
Journal:  Curr Rheumatol Rep       Date:  2014-04       Impact factor: 4.592
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.